nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—Dacarbazine—muscle cancer	0.239	0.323	CbGbCtD
Dapagliflozin—CYP1A2—Dacarbazine—muscle cancer	0.107	0.144	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—muscle cancer	0.0811	0.109	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—muscle cancer	0.0523	0.0705	CbGbCtD
Dapagliflozin—ABCB1—Vincristine—muscle cancer	0.0499	0.0673	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—muscle cancer	0.0457	0.0616	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—muscle cancer	0.0312	0.042	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—muscle cancer	0.0302	0.0407	CbGbCtD
Dapagliflozin—CYP3A4—Vincristine—muscle cancer	0.0299	0.0403	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—muscle cancer	0.0294	0.0396	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—muscle cancer	0.0274	0.0369	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—muscle cancer	0.0187	0.0252	CbGbCtD
Dapagliflozin—Carcinogenicity—Methotrexate—muscle cancer	0.0175	0.125	CcSEcCtD
Dapagliflozin—SLC5A4—renal system—muscle cancer	0.0129	0.109	CbGeAlD
Dapagliflozin—SLC5A2—renal system—muscle cancer	0.00979	0.0829	CbGeAlD
Dapagliflozin—SLC5A11—tendon—muscle cancer	0.00916	0.0776	CbGeAlD
Dapagliflozin—SLC5A4—head—muscle cancer	0.00865	0.0732	CbGeAlD
Dapagliflozin—SLC5A11—head—muscle cancer	0.00785	0.0665	CbGeAlD
Dapagliflozin—SLC5A1—renal system—muscle cancer	0.00742	0.0628	CbGeAlD
Dapagliflozin—SLC5A2—vagina—muscle cancer	0.00709	0.0601	CbGeAlD
Dapagliflozin—SLC5A1—cardiac atrium—muscle cancer	0.00665	0.0563	CbGeAlD
Dapagliflozin—SLC5A2—testis—muscle cancer	0.00633	0.0536	CbGeAlD
Dapagliflozin—UGT2B4—cardiac atrium—muscle cancer	0.00612	0.0519	CbGeAlD
Dapagliflozin—Balanitis—Doxorubicin—muscle cancer	0.00557	0.0398	CcSEcCtD
Dapagliflozin—SLC5A1—vagina—muscle cancer	0.00538	0.0455	CbGeAlD
Dapagliflozin—SLC5A1—testis—muscle cancer	0.0048	0.0406	CbGeAlD
Dapagliflozin—UGT1A9—renal system—muscle cancer	0.00467	0.0396	CbGeAlD
Dapagliflozin—UGT2B7—renal system—muscle cancer	0.00377	0.0319	CbGeAlD
Dapagliflozin—Extravasation—Dactinomycin—muscle cancer	0.00279	0.02	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Doxorubicin—muscle cancer	0.00268	0.0191	CcSEcCtD
Dapagliflozin—Extravasation—Vincristine—muscle cancer	0.0025	0.0178	CcSEcCtD
Dapagliflozin—UGT2B7—testis—muscle cancer	0.00243	0.0206	CbGeAlD
Dapagliflozin—Phlebitis—Dactinomycin—muscle cancer	0.00205	0.0147	CcSEcCtD
Dapagliflozin—Extravasation—Etoposide—muscle cancer	0.00202	0.0144	CcSEcCtD
Dapagliflozin—Urine output increased—Vincristine—muscle cancer	0.00197	0.0141	CcSEcCtD
Dapagliflozin—CYP2A6—vagina—muscle cancer	0.00195	0.0166	CbGeAlD
Dapagliflozin—Multiple fractures—Methotrexate—muscle cancer	0.00182	0.013	CcSEcCtD
Dapagliflozin—Fracture—Methotrexate—muscle cancer	0.00182	0.013	CcSEcCtD
Dapagliflozin—Polyuria—Vincristine—muscle cancer	0.0018	0.0129	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Doxorubicin—muscle cancer	0.00174	0.0124	CcSEcCtD
Dapagliflozin—Venous thrombosis—Doxorubicin—muscle cancer	0.00169	0.0121	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Doxorubicin—muscle cancer	0.00167	0.012	CcSEcCtD
Dapagliflozin—Hyponatraemia—Vincristine—muscle cancer	0.00159	0.0113	CcSEcCtD
Dapagliflozin—Pain in extremity—Vincristine—muscle cancer	0.00158	0.0113	CcSEcCtD
Dapagliflozin—Lung disorder—Methotrexate—muscle cancer	0.00149	0.0107	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Doxorubicin—muscle cancer	0.00149	0.0106	CcSEcCtD
Dapagliflozin—Phlebitis—Etoposide—muscle cancer	0.00149	0.0106	CcSEcCtD
Dapagliflozin—Dehydration—Vincristine—muscle cancer	0.00147	0.0105	CcSEcCtD
Dapagliflozin—CYP1A2—renal system—muscle cancer	0.00142	0.012	CbGeAlD
Dapagliflozin—CYP1A1—renal system—muscle cancer	0.0014	0.0118	CbGeAlD
Dapagliflozin—Fungal infection—Methotrexate—muscle cancer	0.00137	0.00978	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—muscle cancer	0.00129	0.00924	CcSEcCtD
Dapagliflozin—Dysuria—Vincristine—muscle cancer	0.00128	0.00913	CcSEcCtD
Dapagliflozin—CYP1A1—cardiac atrium—muscle cancer	0.00125	0.0106	CbGeAlD
Dapagliflozin—Extravasation—Methotrexate—muscle cancer	0.00121	0.00865	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Vincristine—muscle cancer	0.0012	0.00858	CcSEcCtD
Dapagliflozin—Myocardial infarction—Vincristine—muscle cancer	0.00119	0.00853	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—muscle cancer	0.00118	0.00847	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Vincristine—muscle cancer	0.00108	0.00772	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vincristine—muscle cancer	0.00107	0.00768	CcSEcCtD
Dapagliflozin—Urethral disorder—Vincristine—muscle cancer	0.00107	0.00766	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—muscle cancer	0.00107	0.00766	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—muscle cancer	0.00105	0.00749	CcSEcCtD
Dapagliflozin—CYP3A4—renal system—muscle cancer	0.00103	0.00869	CbGeAlD
Dapagliflozin—CYP1A1—vagina—muscle cancer	0.00101	0.00858	CbGeAlD
Dapagliflozin—CYP2D6—renal system—muscle cancer	0.00101	0.00855	CbGeAlD
Dapagliflozin—Vaginal infection—Methotrexate—muscle cancer	0.000997	0.00713	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—muscle cancer	0.000987	0.00705	CcSEcCtD
Dapagliflozin—Infestation—Etoposide—muscle cancer	0.000987	0.00705	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—muscle cancer	0.000986	0.00705	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Etoposide—muscle cancer	0.000973	0.00695	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—muscle cancer	0.00097	0.00693	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—muscle cancer	0.000967	0.00691	CcSEcCtD
Dapagliflozin—ABCB1—embryo—muscle cancer	0.000959	0.00813	CbGeAlD
Dapagliflozin—Neoplasm—Methotrexate—muscle cancer	0.000955	0.00683	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—muscle cancer	0.000955	0.00683	CcSEcCtD
Dapagliflozin—CYP1A1—head—muscle cancer	0.000935	0.00792	CbGeAlD
Dapagliflozin—Back pain—Vincristine—muscle cancer	0.000921	0.00658	CcSEcCtD
Dapagliflozin—Discomfort—Dactinomycin—muscle cancer	0.000896	0.0064	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—muscle cancer	0.000882	0.0063	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—muscle cancer	0.000875	0.00625	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—muscle cancer	0.000873	0.00624	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—muscle cancer	0.000869	0.00621	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—muscle cancer	0.000868	0.00621	CcSEcCtD
Dapagliflozin—Infection—Dactinomycin—muscle cancer	0.000864	0.00617	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—muscle cancer	0.000864	0.00617	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—muscle cancer	0.000864	0.00617	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—muscle cancer	0.000827	0.00591	CcSEcCtD
Dapagliflozin—Hypertension—Vincristine—muscle cancer	0.000822	0.00587	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—muscle cancer	0.000783	0.00559	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vincristine—muscle cancer	0.000777	0.00555	CcSEcCtD
Dapagliflozin—Oedema—Vincristine—muscle cancer	0.000777	0.00555	CcSEcCtD
Dapagliflozin—Infection—Vincristine—muscle cancer	0.000772	0.00552	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—muscle cancer	0.000771	0.00551	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—muscle cancer	0.000763	0.00546	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Vincristine—muscle cancer	0.000751	0.00537	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—muscle cancer	0.000746	0.00533	CcSEcCtD
Dapagliflozin—ABCB1—renal system—muscle cancer	0.000726	0.00615	CbGeAlD
Dapagliflozin—Hypotension—Vincristine—muscle cancer	0.000726	0.00519	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—muscle cancer	0.000687	0.00491	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—muscle cancer	0.00068	0.00486	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000678	0.00484	CcSEcCtD
Dapagliflozin—CYP2D6—head—muscle cancer	0.000675	0.00572	CbGeAlD
Dapagliflozin—Gastrointestinal disorder—Vincristine—muscle cancer	0.000671	0.00479	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—muscle cancer	0.000667	0.00477	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—muscle cancer	0.000666	0.00476	CcSEcCtD
Dapagliflozin—Constipation—Vincristine—muscle cancer	0.000664	0.00475	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—muscle cancer	0.000664	0.00475	CcSEcCtD
Dapagliflozin—CYP2D6—testis—muscle cancer	0.000653	0.00553	CbGeAlD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000652	0.00466	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—muscle cancer	0.000649	0.00464	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—muscle cancer	0.000641	0.00458	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—muscle cancer	0.000629	0.0045	CcSEcCtD
Dapagliflozin—Infection—Etoposide—muscle cancer	0.000625	0.00447	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—muscle cancer	0.000622	0.00445	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—muscle cancer	0.00062	0.00443	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—muscle cancer	0.000618	0.00441	CcSEcCtD
Dapagliflozin—Body temperature increased—Vincristine—muscle cancer	0.000614	0.00439	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—muscle cancer	0.000611	0.00437	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—muscle cancer	0.000608	0.00435	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000606	0.00433	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—muscle cancer	0.000594	0.00424	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—muscle cancer	0.000591	0.00422	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—muscle cancer	0.000591	0.00422	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—muscle cancer	0.000588	0.0042	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—muscle cancer	0.000581	0.00415	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—muscle cancer	0.000574	0.0041	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vincristine—muscle cancer	0.000572	0.00409	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—muscle cancer	0.000559	0.004	CcSEcCtD
Dapagliflozin—ABCB1—bone marrow—muscle cancer	0.000549	0.00465	CbGeAlD
Dapagliflozin—Rash—Dactinomycin—muscle cancer	0.000548	0.00392	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—muscle cancer	0.000543	0.00388	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—muscle cancer	0.000538	0.00385	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—muscle cancer	0.000537	0.00384	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—muscle cancer	0.00053	0.00379	CcSEcCtD
Dapagliflozin—ABCB1—vagina—muscle cancer	0.000526	0.00445	CbGeAlD
Dapagliflozin—Urinary tract disorder—Methotrexate—muscle cancer	0.000524	0.00374	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—muscle cancer	0.00052	0.00372	CcSEcCtD
Dapagliflozin—Nausea—Dactinomycin—muscle cancer	0.000516	0.00369	CcSEcCtD
Dapagliflozin—Dizziness—Vincristine—muscle cancer	0.000514	0.00367	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—muscle cancer	0.000512	0.00366	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—muscle cancer	0.000512	0.00366	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—muscle cancer	0.000503	0.0036	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—muscle cancer	0.0005	0.00357	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—muscle cancer	0.000497	0.00356	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—muscle cancer	0.000497	0.00356	CcSEcCtD
Dapagliflozin—Rash—Vincristine—muscle cancer	0.00049	0.0035	CcSEcCtD
Dapagliflozin—Dermatitis—Vincristine—muscle cancer	0.000489	0.0035	CcSEcCtD
Dapagliflozin—Headache—Vincristine—muscle cancer	0.000487	0.00348	CcSEcCtD
Dapagliflozin—ABCB1—head—muscle cancer	0.000486	0.00411	CbGeAlD
Dapagliflozin—ABCB1—testis—muscle cancer	0.000469	0.00397	CbGeAlD
Dapagliflozin—Hypersensitivity—Etoposide—muscle cancer	0.000464	0.00331	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—muscle cancer	0.000462	0.0033	CcSEcCtD
Dapagliflozin—Nausea—Vincristine—muscle cancer	0.000461	0.0033	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—muscle cancer	0.000454	0.00324	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—muscle cancer	0.000451	0.00323	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—muscle cancer	0.00045	0.00322	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—muscle cancer	0.000447	0.00319	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—muscle cancer	0.000416	0.00297	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—muscle cancer	0.0004	0.00286	CcSEcCtD
Dapagliflozin—Rash—Etoposide—muscle cancer	0.000397	0.00284	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—muscle cancer	0.000396	0.00283	CcSEcCtD
Dapagliflozin—Headache—Etoposide—muscle cancer	0.000394	0.00282	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00039	0.00279	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—muscle cancer	0.000388	0.00278	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—muscle cancer	0.000387	0.00276	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—muscle cancer	0.000377	0.00269	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—muscle cancer	0.000374	0.00268	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—muscle cancer	0.000374	0.00267	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—muscle cancer	0.000366	0.00262	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—muscle cancer	0.000364	0.0026	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—muscle cancer	0.000352	0.00252	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—muscle cancer	0.000345	0.00247	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000338	0.00242	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—muscle cancer	0.000336	0.0024	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—muscle cancer	0.000326	0.00233	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—muscle cancer	0.000326	0.00233	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000325	0.00233	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—muscle cancer	0.000324	0.00232	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—muscle cancer	0.000317	0.00227	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—muscle cancer	0.000316	0.00226	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—muscle cancer	0.000305	0.00218	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—muscle cancer	0.000299	0.00214	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—muscle cancer	0.000298	0.00213	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000282	0.00201	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—muscle cancer	0.000279	0.00199	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—muscle cancer	0.000278	0.00198	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—muscle cancer	0.000259	0.00185	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—muscle cancer	0.000258	0.00184	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—muscle cancer	0.000249	0.00178	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—muscle cancer	0.00024	0.00172	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—muscle cancer	0.000238	0.0017	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—muscle cancer	0.000237	0.0017	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—muscle cancer	0.000236	0.00169	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—muscle cancer	0.000224	0.0016	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—muscle cancer	0.000216	0.00154	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—muscle cancer	0.000206	0.00147	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—muscle cancer	0.000206	0.00147	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—muscle cancer	0.000204	0.00146	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—muscle cancer	0.000194	0.00139	CcSEcCtD
